Your browser doesn't support javascript.
loading
Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3.
Biedzka-Sarek, Marta; Metso, Jari; Kateifides, Andreas; Meri, Taru; Jokiranta, T Sakari; Muszynski, Artur; Radziejewska-Lebrecht, Joanna; Zannis, Vassilis; Skurnik, Mikael; Jauhiainen, Matti.
Afiliação
  • Biedzka-Sarek M; Department of Chronic Disease Prevention, Public Health Genomics Research Unit, National Institute for Health and Welfare, and Institute for Molecular Medicine Finland (FIMM), 00290 Helsinki, Finland. Electronic address: marta.biedzka-sarek@thl.fi.
  • Metso J; Department of Chronic Disease Prevention, Public Health Genomics Research Unit, National Institute for Health and Welfare, and Institute for Molecular Medicine Finland (FIMM), 00290 Helsinki, Finland.
  • Kateifides A; Department of Molecular Genetics, Boston University Medical Center, Boston, Massachusetts 02118.
  • Meri T; Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, 00014 Helsinki, Finland; Department of Laboratory Diagnostics, Helsinki University Central Hospital, 00290 Helsinki, Finland.
  • Jokiranta TS; Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, 00014 Helsinki, Finland.
  • Muszynski A; Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602.
  • Radziejewska-Lebrecht J; Institute of Microbiology, University of Silesia, 40 032 Katowice, Poland.
  • Zannis V; Department of Molecular Genetics, Boston University Medical Center, Boston, Massachusetts 02118.
  • Skurnik M; Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, 00014 Helsinki, Finland; Department of Laboratory Diagnostics, Helsinki University Central Hospital, 00290 Helsinki, Finland.
  • Jauhiainen M; Department of Chronic Disease Prevention, Public Health Genomics Research Unit, National Institute for Health and Welfare, and Institute for Molecular Medicine Finland (FIMM), 00290 Helsinki, Finland.
J Biol Chem ; 286(44): 38211-38219, 2011 Nov 04.
Article em En | MEDLINE | ID: mdl-21896489
Apolipoprotein A-I (apoA-I), the main protein component of high density lipoprotein (HDL), is well recognized for its antiatherogenic, antioxidant, and antiinflammatory properties. Here, we report a novel role for apoA-I as a host defense molecule that contributes to the complement-mediated killing of an important gastrointestinal pathogen, Gram-negative bacterium Yersinia enterocolitica. We specifically show that the C-terminal domain of apoA-I is the effector site providing the bactericidal activity. Although the presence of the lipopolysaccharide O-antigen on the bacterial surface is absolutely required for apoA-I to kill the bacteria, apoA-I does not interact with the bacteria directly. To the contrary, exposure of the bacteria by serum proteins triggers apoA-I deposition on the bacterial surface. As our data show that both purified lipid-free and HDL-associated apoA-I displays anti-bacterial potential, apoA-I mimetic peptides may be a promising therapeutic agent for the treatment of certain Gram-negative infections.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Yersinia enterocolitica / Apolipoproteína A-I / Antígenos O / Antibacterianos Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Yersinia enterocolitica / Apolipoproteína A-I / Antígenos O / Antibacterianos Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2011 Tipo de documento: Article